Determining the Immunohistochemical Expression of GLUT1 in Renal Cell Carcinoma Using the HSCORE Method

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2021 Aug 25

PMID 34429965

Citations 4

Authors

Marin Ogorevc

Ante Strikic

Sandra Zekic Tomas

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to compare the immunohistochemical expression of glucose transporter 1 (GLUT1) between the most common histological types of renal cell carcinoma (RCC), and to determine whether a correlation between GLUT1 expression and nuclear grade or tumor size exists. A total of 19 RCC samples were selected for the study, consisting of 8 clear cell (cc)RCC and 11 non-ccRCC tissues. Immunohistochemistry for GLUT1 was performed on formalin-fixed and paraffin-embedded sections using GLUT1 antibodies. All data analyses were performed using the MedCalc software. There was a higher immunohistochemical expression of GLUT1 in the ccRCC group compared with the non-cc group, but there was no difference in GLUT1 expression between groups of RCCs with differing nuclear grades. No significant correlation between GLUT1 expression and tumor size was found. The higher immunohistochemical expression of GLUT1 in ccRCC may be a contributing factor to the clinical characteristics and behavior of that group of carcinomas. These results suggest that GLUT1 expression cannot be used as a prognostic factor for RCC, but it may be used as a predictive factor in the future.

Citing Articles

Differential expression of and its downstream target in the main subtypes of renal cell carcinoma and their impact on patient survival.

Strikic A, Kokeza J, Ogorevc M, Kelam N, Vukoja M, dolonga P Front Oncol. 2023; 13:1287239.

PMID: 38053655 PMC: 10694430. DOI: 10.3389/fonc.2023.1287239.

Genetic and Epigenetic Characteristics in Isolated Pancreatic Metastases of Clear-Cell Renal Cell Carcinoma.

Sellner F, Comperat E, Klimpfinger M Int J Mol Sci. 2023; 24(22).

PMID: 38003482 PMC: 10671160. DOI: 10.3390/ijms242216292.

The Effect of GLUT1 and HIF-1α Expressions on Glucose Uptake and Patient Survival in Non-Small-Cell Lung Carcinoma.

Kokeza J, Strikic A, Ogorevc M, Kelam N, Vukoja M, Dilber I Int J Mol Sci. 2023; 24(13).

PMID: 37445752 PMC: 10341668. DOI: 10.3390/ijms241310575.

Genetic evidence that uptake of the fluorescent analog 2NBDG occurs independently of known glucose transporters.

DSouza L, Wright S, Bhattacharya D PLoS One. 2022; 17(8):e0261801.

PMID: 36001583 PMC: 9401136. DOI: 10.1371/journal.pone.0261801.

References

Grahame Hardie D, Ashford M . AMPK: regulating energy balance at the cellular and whole body levels. Physiology (Bethesda). 2014; 29(2):99-107. PMC: 3949207. DOI: 10.1152/physiol.00050.2013. View

Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y . Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004; 109(6):926-32. DOI: 10.1002/ijc.20057. View

Padala S, Barsouk A, Thandra K, Saginala K, Mohammed A, Vakiti A . Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020; 11(3):79-87. PMC: 7239575. DOI: 10.14740/wjon1279. View

Page T, Hodgkinson A, Ollerenshaw M, Hammonds J, Demaine A . Glucose transporter polymorphisms are associated with clear-cell renal carcinoma. Cancer Genet Cytogenet. 2005; 163(2):151-5. DOI: 10.1016/j.cancergencyto.2005.07.004. View

Melstrom L, Salabat M, Ding X, Milam B, Strouch M, Pelling J . Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008; 37(4):426-31. DOI: 10.1097/MPA.0b013e3181735ccb. View

Nagase Y, Takata K, Moriyama N, Aso Y, Murakami T, Hirano H . Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol. 1995; 153(3 Pt 1):798-801. View

Hatanaka M . Transport of sugars in tumor cell membranes. Biochim Biophys Acta. 1974; 355(1):77-104. DOI: 10.1016/0304-419x(74)90008-0. View

Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R . GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001; 92(5):1144-50. DOI: 10.1002/1097-0142(20010901)92:5<1144::aid-cncr1432>3.0.co;2-t. View

Motzer R, Jonasch E, Agarwal N, Bhayani S, Bro W, Chang S . Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(6):804-834. DOI: 10.6004/jnccn.2017.0100. View

10.

Wang J, Ye C, Chen C, Xiong H, Xie B, Zhou J . Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017; 8(10):16875-16886. PMC: 5370007. DOI: 10.18632/oncotarget.15171. View

11.

Kobayashi M, Uematsu T, Tokura Y, Takei K, Sakamoto K, Narimatsu T . Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications. Int Braz J Urol. 2018; 45(1):169-178. PMC: 6442141. DOI: 10.1590/S1677-5538.IBJU.2018.0271. View

12.

Semenza G . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33(4):207-14. PMC: 3437546. DOI: 10.1016/j.tips.2012.01.005. View

13.

Haber R, Rathan A, Weiser K, Pritsker A, Itzkowitz S, Bodian C . GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998; 83(1):34-40. DOI: 10.1002/(sici)1097-0142(19980701)83:1<34::aid-cncr5>3.0.co;2-e. View

14.

Navale A, Paranjape A . Glucose transporters: physiological and pathological roles. Biophys Rev. 2017; 8(1):5-9. PMC: 5425736. DOI: 10.1007/s12551-015-0186-2. View

15.

Chan D, Sutphin P, Nguyen P, Turcotte S, Lai E, Banh A . Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011; 3(94):94ra70. PMC: 3683134. DOI: 10.1126/scitranslmed.3002394. View

16.

Barron C, Bilan P, Tsakiridis T, Tsiani E . Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 2016; 65(2):124-39. DOI: 10.1016/j.metabol.2015.10.007. View

17.

Sadri N, Zhang P . Hypoxia-inducible factors: mediators of cancer progression; prognostic and therapeutic targets in soft tissue sarcomas. Cancers (Basel). 2013; 5(2):320-33. PMC: 3730324. DOI: 10.3390/cancers5020320. View

18.

Park S, Lee J, Lee W, Han K . Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma. Nucl Med Biol. 2012; 39(8):1167-72. DOI: 10.1016/j.nucmedbio.2012.07.003. View

19.

Tohma T, Okazumi S, Makino H, Cho A, Mochizuki R, Shuto K . Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: a marker for poor prognosis. Dis Esophagus. 2005; 18(3):185-9. DOI: 10.1111/j.1442-2050.2005.00489.x. View

20.

Nickerson M, Jaeger E, Shi Y, Durocher J, Mahurkar S, Zaridze D . Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008; 14(15):4726-34. PMC: 2629664. DOI: 10.1158/1078-0432.CCR-07-4921. View